Orforglipron Tracker: What to Log on the GLP-1 Pill (2026)

01

Why an oral GLP-1 pill needs a different kind of tracking

If you have read our Wegovy tracker or Ozempic guides, forget the injection-site map — orforglipron is a pill, so there is no needle and no site rotation to log.

Three other things make tracking genuinely useful here:

02

What to track on orforglipron (and why each one matters)

Here is the core orforglipron dataset. Use it as your checklist whether you track on paper, in a spreadsheet, or in an app.

Note there is no injection-site row — the daily-dose and titration-step rows take its place.

Daily dose, timing, and the orforglipron titration schedule

Orforglipron is deliberately started low and increased slowly to reduce gastrointestinal side effects.

Per the FDA label, the schedule is 0.8 mg once daily to start, then increases of at least 30 days apart to 2.5 mg, then 5.5 mg, and — if more weight loss is needed and it is tolerated — 9 mg, 14.5 mg, or a maximum of 17.2 mg once daily (FDA/DailyMed label; Lilly dosing).

Because the strength changes on a calendar, logging which mg you are on and the date it changed is one of the most useful things you can record.

Your prescriber decides each step, and a clean dose log makes that conversation faster.

The biggest practical advantage over the other GLP-1 pills, oral semaglutide (Rybelsus, and the Wegovy pill for weight management), is that orforglipron has no fasting or water-volume rules: take one tablet once daily, with or without food, swallowed whole (FDA label).

Oral semaglutide (Rybelsus or the Wegovy pill), by contrast, must be taken in the morning on an empty stomach with up to 120 mL (about 4 oz, half a glass) of plain water, waiting at least 30 minutes before food, drink, or other pills (Rybelsus FDA label).

That freedom is exactly why a simple daily tracker works so well — the only thing to protect is the daily habit.

The missed-dose rule (worth getting right). Because orforglipron is a daily pill, the rule differs from the weekly-injection rules.

Per the FDA label: if you miss a dose, take it as soon as possible, but don't double up on the next dose; if you miss 7 or more doses in a row, your prescriber may restart you at a lower dose to reduce gastrointestinal side effects (FDA label).

A tracker that shows your daily streak turns this into a glance instead of a guess.

Weight, measurements, and progress photos

Weight is the headline number for an orforglipron weight loss tracker, but it is noisy day to day.

Weigh in at the same time (typically morning, after the bathroom, before eating) and let the trend line — not a single reading — tell the story.

In the phase 3 ATTAIN-1 trial (72 weeks, adults with obesity without diabetes), the highest dose produced an average weight loss of about 11% versus about 2% with placebo, and about 55% of people on that dose lost at least 10% of their body weight (NEJM, 2025; ClinicalTrials.gov NCT05869903).

That is meaningful — though generally less than the ~15–21% seen in the main trials of injectable semaglutide and tirzepatide, a trade-off many people accept for a needle-free pill (see our semaglutide vs. tirzepatide guide for the injectable numbers).

Plateaus are common and medically explainable; waist measurements and photos every 2–4 weeks capture body-composition change the scale hides.

Protein, food, and protecting muscle

This is the most under-appreciated part of any GLP-1 journey.

Because orforglipron sharply reduces appetite, a meaningful share of the weight you lose can be lean body mass — reviews of GLP-1 trials put it at roughly 20–30% of lost weight on average, with wide variation between studies (and lean mass includes water and organ tissue, not only skeletal muscle) (review in IJMS, 2025).

Muscle protects your metabolism and long-term results. Two trackable habits do the heavy lifting:

1. Protein. Aim for a protein target at each meal. When appetite drops, protein is usually the first thing to fall — so logging it keeps it front of mind.
2. Resistance training. Strength work is the strongest defense against muscle loss on a GLP-1; log your sessions like you log your dose.

Side effects — normal vs. red flag

The most common orforglipron side effects are gastrointestinal — at the highest dose, nausea (about 35%), diarrhea (~25%), constipation (~24%), and vomiting (~24%), plus indigestion, abdominal pain, headache, and fatigue (FDA label).

These usually appear or worsen right after a dose step-up and settle as your body adapts.

Orforglipron also carries a boxed warning for thyroid C-cell tumors and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2 (FDA label).

Rare but serious risks like pancreatitis and gallbladder disease need prompt medical assessment.

Logging what you felt, how severe, and how many days since your last dose step-up turns a vague "I've felt off" into a clear pattern.

For the full symptom-by-symptom breakdown, see our guide to GLP-1 side effects.

If you use birth-control pills: the US Foundayo label advises switching to a non-oral method or adding a barrier method for 30 days after starting and for 30 days after each dose increase.

Safety basics for any GLP-1 log. Don't use these medicines if you or a close relative has had medullary thyroid cancer, or if you have MEN 2.

They are not used during pregnancy — tell your prescriber right away if you become pregnant or plan to, because some must be stopped weeks to months beforehand.

If you also take insulin or a sulfonylurea, watch for low blood sugar (shakiness, sweating, confusion).

Vomiting or diarrhea that keeps you from holding down fluids can dehydrate you and strain your kidneys — call your clinician.

A tracker organizes your records; the package leaflet in your country and your prescriber come first.

03

How to build an orforglipron tracking routine in 6 steps

You do not need a complicated system — you need a repeatable one. This takes seconds a day plus a quick weekly review.

1. 1

   Set a daily pill reminder.

   Pick a consistent time and set a recurring alert so a missed pill never sneaks up on you.

2. 2

   Check off the dose right after taking it.

   A one-tap "taken" builds a visible streak — the single best predictor of results.

3. 3

   Log each titration step.

   When your prescriber moves you up (2.5 → 5.5 → 9 → 14.5 → 17.2 mg), record the new mg and the date.

4. 4

   Weigh in on fixed days.

   Choose 1–3 mornings a week, same conditions, and read the trend — not the daily noise.

5. 5

   Track protein and water daily, and note side effects when they happen.

   Record the symptom, severity, and days since your last step-up.

6. 6

   Photo every 2–4 weeks and review before each visit.

   Same lighting, same angle — and bring your dose log and side-effect timeline to your clinician.

04

Do you need an orforglipron app, or is a notebook fine?

Honestly, any tracking beats none — an orforglipron diary in a notebook works.

What an app adds is the automation of the parts people forget: the daily reminder, the adherence streak, the titration-step history, the trend line that smooths daily weight noise, and a side-effect timeline you can hand to your clinician.

Orforglipron does not ship with a dedicated companion app, so most people use a general GLP-1 or wellness tracker.

If you want your dose log living next to the daily habits that protect your results — protein, movement, hydration, weight and body-composition trends — a wellness app like HAVIT is a natural home for it.

Compare a few options in our best GLP-1 tracker apps guide and pick what you will actually keep using; consistency matters far more than the brand.

05

Related guides

• Wegovy tracker: what to log on the weekly injection
• Ozempic tracker: what to log on Ozempic and how
• GLP-1 side effects: nausea, GI symptoms & red flags
• The complete GLP-1 tracker app guide

06

Why HAVIT — Medication + Behavior Change, in One App

GLP-1 medications can meaningfully reduce weight — but the number on the scale is only part of the story.

A meaningful share of the weight lost on GLP-1 therapy can come from lean tissue rather than fat — estimates range from about 15% or less to 40–60% across studies (Neeland et al., Diabetes, Obesity and Metabolism, 2024), and results tend to fade once the medication stops unless new habits take their place.

That's why leading guidance treats medication as one part of care, not the whole: the U.S. Preventive Services Task Force recommends that adults with obesity be offered intensive, multicomponent behavioral interventions (USPSTF, Grade B).

HAVIT is built for exactly this moment — one app that unites medication tracking, body composition, nutrition and protein, daily habit-building, and an AI coach that adapts to you.

Across our own 1,090 GLP-1 users, the most consistent trackers built the strongest habits (see the GLP-1 habit report).

Manage the medicine and the muscle — together. Start with HAVIT →

Related articles